Angle’s Parsortix System Outperforms Density Centrifugation Method For Isolating Tumor Cells

Angle PLC, announced a significant milestone as a recent study conducted by researchers at the University of Tubingen in Germany demonstrates that Angle’s Parsortix system surpasses the current laboratory standard for disseminated tumor cell (DTC) harvesting.

The study, featured in the International Journal of Molecular Sciences, focused on disseminated tumor cells found in the bone marrow of breast cancer patients. Researchers at the University of Tubingen employed Angle’s Parsortix system for the isolation and harvest of DTCs from bone marrow samples of 360 breast cancer patients. Their findings were then compared to the results obtained using the standard density centrifugation method for DTC detection.

The Parsortix system is a proprietary new technology developed by Angledesigned for the harvesting of circulating tumor cells (CTCs). This technology enables comprehensive downstream analysis of samples, including whole cell imaging, proteomic analysis, and full genomic and transcriptomic molecular analysis. The system is the first FDA cleared medical device for the capture and harvest of intact CTCs from metastatic breast cancer patient blood. As of June the company had placed 290 instruments worldwide and the technology had been used to process 192,000 samples cumulatively.

The study revealed several key advantages of the Parsortix system over the traditional methods including the fact that the Parsortix system was found to be more user-friendly, simplifying the process of DTC isolation and harvest. Additionally, the Parsortix system yielded significantly higher numbers of DTCs for further analysis compared to the standard density centrifugation method. Furthermore, the isolated DTCs collected using Parsortix were abundant and viable, a feat not achieved with the standard method. Angle asserts that these findings open up new possibilities for DTC characterization, including the assessment of biomarker status, which is crucial for selecting targeted treatments and assessing prognosis.

Karen Miller, Chief Scientific Officer at Angle, expressed her satisfaction with the study’s results, saying, “We are pleased to share the peer-reviewed publication by the University of Tubingen that demonstrates consistently high performance of the Parsortix system for the harvest of DTCs as opposed to CTCs. This is the second study center to demonstrate successful enrichment and harvest of DTCs from bone marrow aspirate, highlighting a range of additional potential uses of the Parsortix system in clinical practice.”